β-hydroxy-β-methylbutyrate-enriched Nutritional Supplements for Obesity Adults

β-hydroxy-β-methylbutyrate-enriched Nutritional Supplements for Obesity Adults During Weight Loss: a Randomized Double-blind Placebo-controlled Clinical Trial

The purpose of this study is to assess the effectiveness and safety of HMB-enriched nutritional supplements for improving muscle mass and muscle function in Chinese adults with obesity during the weight loss process using calorie restriction.

Study Overview

• Status: Not yet recruiting
• Conditions: Obesity
• Intervention / Treatment: Dietary supplement: HMB-enriched Nutritional Supplements; Behavioral: Caloric Restrition Diet; Dietary supplement: Placebo

• Study Type: Interventional
• Enrollment (Anticipated): 72
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Yuxaing Liang; Phone Number: 0086-13982250862; Email: yx45liang@sina.com

Study Locations

• China
  • Sichuan
    • Chengdu, Sichuan, China, 610064
      • West China Hospital,Sichuan University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 30 years to 50 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Men and women aged 30-50 years
2. Currently having obesity defined by body mass index (BMI) ≥ 28 kg/m2 (based on measured body weight and height at booking, using validated scales)
3. Having an intention to lost weight via caloric restriction
4. Apparently healthy and able to walk independently
5. Able to eat independently to meet their energy needs
6. Without significant body weight change in the last 6 month (less than 5% change in body weight)
7. Having sedentary habit defined by Sedentary Behavior Research Network
8. Able to collaborate with the research staff.

Exclusion Criteria:

1. Having a history of intolerance to enteral nutrition, food (e.g., lactose intolerance), or being allergic to the components of our HMB-enriched nutritional supplements (e.g., soy or corn);
2. Having any implants (e.g., pacemakers);
3. Current use of other nutritional supplements or drugs that may have an impact on the effectiveness of the intervention (e.g., glucocorticoids, antineoplastic drugs, antituberculosis drugs, sedatives, antipsychotics, muscle relaxants, monoamine oxidase inhibitors, antibiotics) within 3 months prior to enrollment;
4. Secondary obesity caused by diseases (e.g., hypothalamic diseases and hypercortisolism) or drugs (e.g. glucocorticoids, insulin, tricyclic antidepressants);
5. Clinically visible edema;
6. Trauma, surgery, hospitalization, fall, or fracture within 6 months prior to enrollment;
7. Pregnancy, having pregnancy plans, or lactation;
8. Individuals who are participating in other clinical trials; any acute illness (e.g., acute infection, myocardial infarction, arrhythmia, myocarditis, appendicitis, etc.);
9. Swallowing disorders; abnormal thyroid function (including hyperthyroidism and hypothyroidism);
10. Having a history of diabetes, respiratory diseases, cardiovascular diseases, uncontrolled hypertension, kidney diseases, digestive system diseases, renal insufficiency, mental illness, neurological diseases, hematologic diseases, liver diseases (except for fatty liver), chronic infection (e.g., tuberculosis), immune system diseases, joint disorders, any type of tumor;
11. Alcohol consumption over two standard alcoholic beverages (20 g of alcohol/day);
12. Difficulty to comply with the study protocol;
13. Other conditions that indicate the individuals are inappropriate for participation in this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: HMB; The participants will receive oral HMB-enriched nutritional supplements (65 g once daily)	Dietary supplement: HMB-enriched Nutritional Supplements; The participants will receive oral HMB-enriched nutritional supplements (65 g, once daily), which include soybean isolate protein, flaxseed oil powder, yam powder, whey protein, oligomeric isomaltose powder, cocoa powder, medium-chain fatty acid powder, calcium beta-hydroxy-beta-methylbutyrate, sunflower seed oil powder, L-glutamine, wheat germ powder, membrane isolated casein, wheat oligopeptide, konjac flour, vitamin E, vitamin D, stevioside, edible flavors.; Behavioral: Caloric Restrition Diet; Caloric restriction diet with individualized nutritional guidance from professional dietitians by video regarding caloric restriction strategies
Placebo Comparator: Placebo; The participants will receive a placebo (maltodextrin 65 g once daily) with the same package as the intervention.	Behavioral: Caloric Restrition Diet; Caloric restriction diet with individualized nutritional guidance from professional dietitians by video regarding caloric restriction strategies; Dietary supplement: Placebo; Placebo (maltodextrin 65 g once daily) with the same package as the intervention.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The mean change in whole-body skeletal muscle mass (SMM)	The whole-body skeletal muscle mass (SMM)	12 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The mean change in appendicular skeletal muscle mass (ASMM)	These data will be measured using InBody 770 (Biospace Co., Seoul, Korea).	12 weeks
The mean change in trunk skeletal muscle mass (TSMM)	These data will be measured using InBody 770 (Biospace Co., Seoul, Korea).	12 weeks
The mean change in total body fat mass (BFM)	These data will be measured using InBody 770 (Biospace Co., Seoul, Korea).	12 weeks
The mean change in total appendicular body fat mass (ABFM)	These data will be measured using InBody 770 (Biospace Co., Seoul, Korea).	12 weeks
The mean change in trunk body fat mass (TBFM)	These data will be measured using InBody 770 (Biospace Co., Seoul, Korea).	12 weeks
The mean change in basal metabolic rate (BMR)	These data will be measured using InBody 770 (Biospace Co., Seoul, Korea).	12 weeks
The mean change in phase angle (PA)	These data will be measured using InBody 770 (Biospace Co., Seoul, Korea).	12 weeks
The mean change in body weight (BW)	These data will be measured using InBody 770 (Biospace Co., Seoul, Korea).	12 weeks
The mean change in handgrip strength (HGS)	A trained nurse will measure HGS using a digital handheld dynamometer (EH101; Xiangshan Inc, Guangdong, China) to the nearest 0.1 kg .	6 and 12 weeks
The mean change in waist circumference	A trained nurse will measure waist circumference using a tape at the level midway between the lower rib margin and the iliac crest with the participant breathing out gently.	6 and 12 weeks
The mean change in hip circumference	Hip circumference was measured as the maximum circumference over the buttocks	6 and 12 weeks
The mean change in physical activity	It will be measured using self-reported International Physical Activity Questionnaire Short Form (IPAQ-SF).The International Physical Activity Questionnaires (IPAQ) comprises a set of 4 questionnaires. Long (5 activity domains asked independently) and short (4 generic items) versions for use by either telephone or self-administered methods are available. The purpose of the questionnaires is to provide common instruments that can be used to obtain internationally comparable data on health related physical activity.	From the beginning to weeks 3, 6, 9, and 12.
The mean change in the score of the sit-to-stand test	A trained nurse will perform the 30-second sit-to-stand test ,which is a classic test for measuring the performance of lower extremity muscles.	6 and 12 weeks
The mean change in energy intake	It will be measured for all participants using the self-reported Food Frequency Questionnaire (FFQ)	From the beginning to weeks 3, 6, 9, and 12
The mean change in lipid profiles	It will be tested using standard method.	12 weeks
The mean change in fasting glucose	It will be tested using standard method.	12 weeks
The mean change in fasting insulin	It will be tested using standard method.	12 weeks
The mean change in HOMA-IR	It will be tested using standard method.	12 weeks
The mean change in albumin	It will be tested using standard method.	12 weeks

Collaborators and Investigators

• Sponsor: West China Hospital
• Investigators: Study Director: Jiaojiao Jiang, West China Hospital; Study Chair: Ming Yang, West China Hospital

Publications and helpful links

General Publications

• Jing X, Liang Y, Wang R, Fu H, Jiang J, Yang M. beta-hydroxy-beta-methylbutyrate-enriched nutritional supplements for obese adults during weight loss: study protocol of a randomised, double-blind, placebo-controlled clinical trial. BMJ Open. 2022 Jun 23;12(6):e055420. doi: 10.1136/bmjopen-2021-055420.

Study record dates

Study Major Dates

• Study Start (Anticipated): September 20, 2021
• Primary Completion (Anticipated): October 31, 2021
• Study Completion (Anticipated): December 31, 2021

Study Registration Dates

• First Submitted: June 12, 2021
• First Submitted That Met QC Criteria: June 28, 2021
• First Posted (Actual): July 8, 2021

Study Record Updates

• Last Update Posted (Actual): September 14, 2021
• Last Update Submitted That Met QC Criteria: September 13, 2021
• Last Verified: September 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Overnutrition; Nutrition Disorders; Overweight; Body Weight; Obesity
• Other Study ID Numbers: 2021（202）

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No